This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. OKLAHOMA CITY (KFOR) – Many doctors, nurses ...
Shattuck Labs Inc (NASDAQ:STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk ...
– Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% – – Observed 27% ...
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results